Search results for: 'android ed point terminals forecast 2024'

This study provides an overview of the global point-of-care testing (POCT) industry, which refers to any routine or specialized lab pathology testing conducted rapidly, on-site/near the site of the patient, where care or treatment is provided. COVID-19 radicalization is changing the global diagnostics landscape. Consolidation trends, structural s...

14 Jul 2022  |  North America  |  Market Research

United States Molecular Point-of-Care Testing Growth Opportunities

Syndromic Point-of-Care Testing Drives Transformational Growth in Infectious Disease Diagnostics

Infographics

×

Rapid advancements in infectious disease diagnostics continue with novel identification methods and healthcare accessibility improvements. The shift from traditional testing to a more technologically empowered, consumer-centric testing encompasses the sample-in-answer-out approach of diagnostic testing that generates results in minutes or hours. Nu...

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as signif...

23 Jun 2016  |  North America  |  Market Research

Growth Opportunities in the US Point-of-care Testing Market

Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics

Infographics

×

The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...

The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...

Femtech is an emerging term and, as is the case with most new concepts, is poorly understood. While some relate Femtech only with products unique to the female anatomy (including consumer products), others dismiss it as just another term for a group of existing solutions. Frost & Sullivan believes it is a unique space and a place for new growth opp...

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage. To understand the trend outlook fo...

17 Mar 2020  |  North America  |  Market Research

Analysis of the Critical Care Patient Monitoring Market, US and EU5, Forecast to 2024

Market to Shift from Stand-alone Monitors to Integrated Solutions and Reach a Size of $13.17 Billion in 2024

Infographics

×

Key Issues Addressed

The economic burden for global critical care is estimated at $270 billion and intensive care unit (ICU) mortality in developed countries is still in the range of 10% to 20%. Advancements in effective patient monitoring in the ICU can not only help reduce the mortality rate but also be beneficial in improving patient and healthcare staff experience....